|
Organization and Summary of Significant Accounting Policies (Details Textual) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 6 Months Ended |
|---|---|---|
|
Mar. 31, 2012
|
Jun. 30, 2012
|
|
| Organization and Summary of Significant Accounting Policies (Textual) [Abstract] | ||
| Collaboration agreement upfront payment | $ 25 | |
| Milestone payments earned | 32.5 | |
| Milestone payments received | 20 | |
| Milestone payment due | 12.5 | |
| Potential milestone payments | $ 22.5 | |
| Merck's percentage share of worldwide development expenses | 70.00% |
| X | ||||||||||
|
- Definition
Collaboration agreement additional potential milestone payments. No definition available.
|
| X | ||||||||||
|
- Definition
Collaboration agreement upfront payment. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Revenue recognition milestone method payment received. No definition available.
|
| X | ||||||||||
|
- Definition
Revenue recognition milestone method remaining payment. No definition available.
|
| X | ||||||||||
|
- Definition
The amount of consideration earned during the period for the milestone or milestones. No definition available.
|
| X | ||||||||||
|
- Definition
Worldwide development expenses share percentage. No definition available.
|